Hively Brad sold $1.9M of STLN

Starling Oncology (STLN) reported Q3 2026 revenue of $169.8M, up 24% YoY, and adjusted EBITDA of $3.4M. The company expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M, targeting 100% capitated revenue growth in 2027, according to management.

Oncology Institute (STLN) reported Q3 gross profit of $30.7M, up from $18.9M, with gross margin increasing to 18.1%. Capitated revenue rose 39.5% to $28.7M, while fee-for-service revenue fell 21% to $31.3M. The company expects 100% capitated revenue growth in 2027 and updated its 2026 outlook, including revenue of $650M-$660M and gross profit of $107M-$110M. STLN ended Q3 with $36.9M in cash.

Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o

Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.

GORDON CARL L purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05.

Johnson Timothy Steven (Chief Executive Officer) purchased 90,000 shares of BLACKSTONE MORTGAGE TRUST, INC. (BXMT) at $11.50 ($1.04M total) on 2026-11-04.